Severely Under Valued Stocks

Star Pharmaceutical

1. Company has been turning around lately and upcoming result will show more clearly the direction

2. Market Capitalisation is half of cash reserves. Stock price is hence extremely undervalued as there is a huge gap between the two values.

3. Based on cash balances alone after net debt, stock price is easily almost twice the current value.

4. Company has recently reported a huge improvement in profit earnings of more than 1000%

5. If the upcoming results continue to improve, the enterprise value gap will increase further as company accumulates more cash

From the annual report 2016 of Star Pharmaceutical::

"We will also continue to develop new products through our R&D efforts to meet changing market needs. Currently, there are 14 on-going R&D projects in progress. Therefore, we expect our continuous investments in R&D to bear fruit soon . With a strong product pipeline, coupled with aggressive business development initiatives to expand domestic sales and capture growth opportunities internally and externally, we are optimistic of delivering a better performance in the future."

I am looking at InnoTek, comparing its valuation versus its peers, InnoTek is severely undervalued. There is no analyst covering this company at all.

a remarkable 555% growth in earnings in its half year financials. Share price lagging way behind net cash per share

GSS ENERGY 15.3 cents, is severely undervalued becos:

1. Its precision engg business trading at discount to peers.
At PE of 10, the stock should be valued at $0.22-23/share.

2. Its oil business is going to hit first oil in a matter of weeks.
The oil reserves of 24 million barrels is easily worth the market cap of GSS Energy currently, ie 15 cents a share.
dyodd

Star Pharmaceuticals has been performing share buy back since last week at 21cents. Even today they are buying back shares at 22cents.